Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan

References

• Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford). 2000;39(Suppl 2):3–12.
   PubMed Web of Science ®Google Scholar
• Lockshin MD. Invited review: sex ratio and rheumatic disease. J Appl Physiol (1985). 2001;91:2366–73.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62:1576–82.
   PubMed Web of Science ®Google Scholar
• Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. Rheum Dis Clin North Am. 2007;33:319–43, vi–vii.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol. 2007;29:185–91.
   PubMed Web of Science ®Google Scholar
• de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum. 2008;59:1241–8.
   PubMed Web of Science ®Google Scholar
• Wallenius M, Salvesen KA, Daltveit AK, Skomsvoll JF. Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry. Acta Obstet Gynecol Scand. 2014;93:302–7.
   PubMed Web of Science ®Google Scholar
• Wallenius M, Salvesen KA, Daltveit AK, Skomsvoll JF. Miscarriage and stillbirth in women with rheumatoid arthritis. J Rheumatol. 2015;42:1570–2.
   PubMed Web of Science ®Google Scholar
• Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol. 2003;30:241–6.
   PubMed Web of Science ®Google Scholar
• Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis. 2014;6:169–84.
   PubMedGoogle Scholar
• Umeda N, Ito S, Hayashi T, Goto D, Matsumoto I, Sumida T. A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Intern Med. 2010;49:187–9.
   PubMed Web of Science ®Google Scholar
• Natsumi I, Matsukawa Y, Miyagawa K, Kodaira H, Tanaka T, Horikoshi A, et al. Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. Rheumatol Int. 2013;33:2433–5.
   PubMed Web of Science ®Google Scholar
• Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis. 2009;68:1793–4.
   PubMed Web of Science ®Google Scholar
• Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can Fam Physician. 2007;53:409–12.
   PubMed Web of Science ®Google Scholar
• Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med. 1995;333:537–40.
   PubMed Web of Science ®Google Scholar
• Skomsvoll JF, Wallenius M, Koksvik HS, Rødevand E, Salvesen KA, Spigset O, et al. Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol. 2007;3:156–64.
   PubMedGoogle Scholar
• Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford). 2007;46:695–8.
   PubMed Web of Science ®Google Scholar
• Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol. 2011;21:10–15.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum. 2008;58:2968–80.
   PubMed Web of Science ®Google Scholar
• Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford). 2012;51:1860–9.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73:69–74.
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:344–54.
   PubMed Web of Science ®Google Scholar
• Prescribing Information: Actemra (tocilizumab) 2013. Available from: http://www.gene.com/download/pdf/actemra_prescribing.pdf Accessed September 20, 2015.
   Google Scholar
• Wakabayashi A, Sawada K, Nakayama M, Toda A, Kimoto A, Mabuchi S, et al. Targeting interleukin-6 receptor inhibits preterm delivery induced by inflammation. Mol Hum Reprod. 2013;19:718–26.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377–85.
   PubMed Web of Science ®Google Scholar
• Calligaro A, Hoxha A, Ruffatti A, Punzi L. Are biological drugs safe in pregnancy? Reumatismo. 2015;66:304–17.
   PubMedGoogle Scholar
• Yamamoto T. Abnormal pregnancy [in Japanese]. Acta Obster Gymnaeccol Jpn. 2007;59:N663–71.
   Google Scholar
• MedlinePlus® 2014; Miscarriage. Available from: http://www.nlm.nih.gov/medlineplus/ency/article/001488.htm Accessed November 16, 2015.
   Google Scholar
• Wilcox AJ, Weinberg CR, O’Connor JF, Baird DD, Schlatterer JP, Canfield RE, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319:189–94.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Goupille P, Moosavi S. First experiences with pregnancies n RA patients (pts) receiving tocilizumab (TCZ) therapy. Arthritis Rheum. 2010;62(Suppl 10):384.
   Google Scholar
• de Man YA, Hazes JM, van der Heide H, Willemsen SP, de Groot CJ, Steegers EA, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 2009;60:3196–206.
   PubMed Web of Science ®Google Scholar
• Østensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, et al. State of the art: reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015;14:376–86.
   PubMed Web of Science ®Google Scholar
• Krajewski P, Sieroszewski P, Karowicz-Bilinska A, Kmiecik M, Chudzik A, Strzalko-Gloskowska B, et al. Assessment of interleukin-6, interleukin-8 and interleukin-18 count in the serum of IUGR newborns. J Matern Fetal Neonatal Med. 2014;27:1142–5.
   PubMed Web of Science ®Google Scholar
• de Steenwinkel FD, Hokken-Koelega AC, de Man YA, de Rijke YB, de Ridder MA, Hazes JM, et al. Circulating maternal cytokines influence fetal growth in pregnant women with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1995–2001.
   PubMed Web of Science ®Google Scholar
• Itabashi K, Miura F, Uehara R, Nakamura Y. New Japanese neonatal anthropometric charts for gestational age at birth. Pediatr Int. 2014;56:702–8.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Network of French Pharmacovigilance C, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101–10.
   PubMed Web of Science ®Google Scholar
• Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368:601–11.
   PubMed Web of Science ®Google Scholar
• Sauer MV. Reproduction at an advanced maternal age and maternal health. Fertil Steril. 2015;103:1136–43.
   PubMed Web of Science ®Google Scholar
• Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL, BSRBR Control Centre Consortium, BSR Biologics Register. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823–6.
   PubMed Web of Science ®Google Scholar